Table 1.
Druggable targets in solid neoplasms modified according to OncoKB.
| Gene | Alteration | Cancer Type |
|---|---|---|
| ALK | Fusions, Oncogenic Mutations | NSCLC |
| ATM | Oncogenic Mutations | Prostate Cancer, NOS, Prostate Cancer |
| BARD1 | Oncogenic Mutations | Prostate Cancer, NOS, Prostate Cancer |
| BRAF | V600 | Melanoma |
| BRAF | V600E | Anaplastic Thyroid Cancer, CRC, NSCLC |
| BRAF | V600E, V600K | Melanoma |
| BRCA1 | Oncogenic Mutations | Ovary/Fallopian Tube, Ovarian Cancer, Peritoneal Serous Carcinoma, Prostate Cancer, NOS, Prostate Cancer |
| BRCA2 | Oncogenic Mutations | Ovary/Fallopian Tube, Ovarian Cancer, Peritoneal Serous Carcinoma, Prostate Cancer, NOS, Prostate Cancer |
| BRIP1 | Oncogenic Mutations | Prostate Cancer, NOS, Prostate Cancer |
| CDK12 | Oncogenic Mutations | Prostate Cancer, NOS, Prostate Cancer |
| CHEK1 | Oncogenic Mutations | Prostate Cancer, NOS, Prostate Cancer |
| CHEK2 | Oncogenic Mutations | Prostate Cancer, NOS, Prostate Cancer |
| EGFR | Exon 19 deletion, L858R | NSCLC |
| EGFR | Exon 20 insertion | NSCLC |
| EGFR | G719 | NSCLC |
| EGFR | L861Q | NSCLC |
| EGFR | S768I | NSCLC |
| EGFR | T790M | NSCLC |
| ERBB2 | Amplification | Breast Cancer, Esophagogastric Cancer |
| FANCL | Oncogenic Mutations | Prostate Cancer, NOS, Prostate Cancer |
| FGFR2 | Fusions | Bladder Cancer, Cholangiocarcinoma |
| FGFR3 | Fusions | Bladder Cancer |
| FGFR3 | G370C, R248C, S249C, Y373C | Bladder Cancer |
| IDH1 | R132 | Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma |
| KIT | A502,Y503dup, K509I, N505I, S476I, S501, A502dup | Gastrointestinal Stromal Tumor |
| KIT | A829P and 5 other alterations | Gastrointestinal Stromal Tumor |
| KIT | D572A and 65 other alterations | Gastrointestinal Stromal Tumor |
| KIT | K642E | Gastrointestinal Stromal Tumor |
| KIT | T670I | Gastrointestinal Stromal Tumor |
| KIT | V654A | Gastrointestinal Stromal Tumor |
| KRAS | G12C | NSCLC |
| KRAS | Wildtype | CRC |
| MET | D1010, Exon 14 deletion, Exon 14 splice mutation | NSCLC |
| NF1 | Oncogenic Mutations | Neurofibroma |
| NRAS | Wildtype | CRC |
| NTRK1 | Fusions | All Solid Tumors |
| NTRK2 | Fusions | All Solid Tumors |
| NTRK3 | Fusions | All Solid Tumors |
| PALB2 | Oncogenic Mutations | Prostate Cancer, NOS, Prostate Cancer |
| PDGFB | COL1A1-PDGFB Fusion | Dermatofibrosarcoma Protuberans |
| PDGFRA | Exon 18 in-frame deletions, Exon 18 in-frame insertions, Exon 18 missense mutations | Gastrointestinal Stromal Tumor |
| PIK3CA | C420R and 10 other alterations | Breast Cancer |
| RAD51B | Oncogenic Mutations | Prostate Cancer, NOS, Prostate Cancer |
| RAD51C | Oncogenic Mutations | Prostate Cancer, NOS, Prostate Cancer |
| RAD51D | Oncogenic Mutations | Prostate Cancer, NOS, Prostate Cancer |
| RAD54L | Oncogenic Mutations | Prostate Cancer, NOS, Prostate Cancer |
| RET | Fusions | NSCLC, Thyroid Cancer |
| RET | Oncogenic Mutations | Medullary Thyroid Cancer |
| ROS1 | Fusions | Non-Small Cell Lung Cancer |
| SMARCB1 | Deletion | Epithelioid Sarcoma |
Abbreviation: NOS = not otherwise specified.